Generation Bio Co (Generation Bio Co) Additional Paid-In Capital : $774.22 Mil(As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Generation Bio Co Additional Paid-In Capital?

Generation Bio Co's quarterly additional paid-in capital increased from Jun. 2023 ($762.23 Mil) to Sep. 2023 ($768.10 Mil) and increased from Sep. 2023 ($768.10 Mil) to Dec. 2023 ($774.22 Mil).

Generation Bio Co's annual additional paid-in capital increased from Dec. 2021 ($689.87 Mil) to Dec. 2022 ($727.34 Mil) and increased from Dec. 2022 ($727.34 Mil) to Dec. 2023 ($774.22 Mil).

Generation Bio Co Additional Paid-In Capital Historical Data

The historical data trend for Generation Bio Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generation Bio Co Additional Paid-In Capital Chart

Generation Bio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

9.86

456.97

689.87

727.34

774.22

Generation Bio Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															727.34	755.96	762.23	768.10	774.22

Generation Bio Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Generation Bio Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Generation Bio Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Generation Bio Co (Generation Bio Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generation Bio Co (NAS:GBIO) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.generationbio.com

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.

Executives

Dannielle Appelhans	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Donald William Nicholson	director	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Anthony G. Quinn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPWY, STE. 250, AUSTIN TX 78746
Antoinette Paone	officer: CHIEF OPERATING OFFICER	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Yalonda Howze	officer: CHIEF LEGAL OFFICER	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Phillip Samayoa	officer: CHIEF STRATEGY OFFICER	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Jason P Rhodes	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, L.p.	10 percent owner	400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Matthew Stanton	officer: Chief Scientific Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Douglas Kerr	officer: Chief Development Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Geoff Mcdonough	director, 10 percent owner, officer: See Remarks	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Tracy Zimmermann	officer: Chief Development Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Cooper Ronald Harold Wilfred	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Mark D. Angelino	officer: Chief Operating Officer	GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142